Gene · 8764
TNFRSF14: TNF receptor superfamily member 14
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TNFRSF14: TNF receptor superfamily member 14. Genes, record 8764. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8764
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q92956 | Tumor necrosis factor receptor superfamily member 14 | 283 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents221
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026019692 A2 | 2026-01-22 | 21 | Q92956 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68659 | Q92956 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7204 | Q92956 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 1062 | Q92956 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7134 | Q92956 | Espacenet |
| EP 4628503 A2 | 2025-10-08 | 28 | Q92956 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 13574 | Q92956 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16610 | Q92956 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16726 | Q92956 | Espacenet |
| EP 4619424 A2 | 2025-09-24 | 30 | Q92956 | Espacenet |
1 to 10 of 221
See all 221 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,851
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TNFRSF14 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 31 | 2025 |
| P30EY001792 | P30 Core Grant for Vision Research | 27 | 2025 |
| ZIASC000550 | Lymphoma Disease Discovery and Definition | 15 | 2025 |
| U19AI070535 | Airway Inflammation and Airway Remodeling in Severe Asthma | 13 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| R01EY024710 | A new molecular therapy against ocular herpes | 12 | 2025 |
| ZIABC011070 | Hematopathology Diagnosis | 9 | 2025 |
| P01CA163205 | Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas | 7 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 7 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 7 | 2025 |
1 to 10 of 1,851Source NIH's project files
See all 1,851 nih grantsPapers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Diagnosis/Treatment Status and Research Progress of Primary Thyroid Lymphoma--Review]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2026 | 42802467 | PubTator, text mining | PubMed |
| Mutant HVEM in lymphoma disrupts BTLA and CD160 regulation of anti-tumor signaling. | Front Immunol | 2026 | 42798506 | PubTator, text mining | PubMed |
| Shared Genetic Basis of Autoimmune Diseases and Follicular Lymphoma by Mendelian Randomization and Multi-Omics. | Genes (Basel) | 2026 | 42792925 | PubTator, text mining | PubMed |
| Beyond PD-L1/PD-1: expression of PVR/TIGIT and TNFRSF14/BTLA axes in response to Helicobacter pylori and in gastric cancer lesions. | Immunohorizons | 2026 | 42772936 | PubTator, text mining | PubMed |
| A multi-omics integrative analyses reveals CYBB-mediated apoptotic and immune dysregulation as a key target of berberine in diffuse large B-cell lymphoma. | Front Pharmacol | 2026 | 42730162 | PubTator, text mining | PubMed |
| Single cell mapping of B and T cell dynamics in breast cancer lymph node metastasis. | Front Bioinform | 2026 | 42656703 | PubTator, text mining | PubMed |
| The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B. | Front Immunol | 2026 | 42638743 | PubTator, text mining | PubMed |
| Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC. | Cancer Gene Ther | 2026 | 42629367 | PubTator, text mining | PubMed |
| Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors. | Mol Cancer Ther | 2026 | 42617197 | PubTator, text mining | PubMed |
| Plasma Metabolomic and Proteomic Profiling of the Mechanisms Underlying the Cumulative Impact of Co-occurring Psychiatric Disorders on Atopic Dermatitis. | Acta Derm Venereol | 2026 | 42549601 | PubTator, text mining | PubMed |
1 to 10 of 3,537
See all 3,537 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8764
GET https://conductscience.org/api/genes/v1/8764/patents?page=2